P3 Health Partners receives Nasdaq bid price deficiency notice; 180-day cure period ends Nov 11, 2024

P3 Health Partners Inc.

Received Nasdaq letter on May 15, 2024 for common stock (PIII) bid price below $1.00 for 31 straight business days.
Must close at $1.00 or higher for at least 10 consecutive business days by November 11, 2024 to regain compliance.
If not compliant by Nov 11, may qualify for an additional 180-day period if other listing standards are met.
Stock remains listed for now; company will evaluate available options to cure the deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.